/
The Company's mission is Serving Patients, Improving Lives by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. In connection with the acquisition, the Company added two new products, ILUVIEN ("ILUVIEN") and YUTIQ ("YUTIQ").
$74.65
$2.06 (-2.69%)
Last close via Marketstack
12.58% operating margin is respectable but not wide. ROIC at 11.78%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 43.8% YoY with margins expanding 12.5pp.
Even for strong businesses, today's 19x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
19.1x earnings, 8.4x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$924M
▲ +43.8% YoY
Net Income (TTM)
$92M
▲ +522.9% YoY
Op. Margin
13.40%
▲ +12.5pp YoY
ROIC
12.10%
▲ +11.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$191M
▲ +258.7% YoY
Op. Cash Flow (TTM)
$209M
▲ +189.3% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$311M
5Y CAGR: +33.5%
5Y CAGR: +79.8%
Continue Research